Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 3—March 2015
Letter

Lack of Effect of Lamivudine on Ebola Virus Replication

Lisa Hensley, Julie Dyall, Gene G. Olinger, and Peter B. JahrlingComments to Author 
Author affiliations: National Institutes of Health, Frederick, Maryland, USA

Main Article

Table

Inhibitory effects of test compounds on Ebola virus replication*

Virus variant or subtype Cell type Lamivudine EC50, μmol/L† Toremifene EC50 ± SD, μmol/L†
EBOV/Kik Vero E6 >80 5.7 ± 0.7
EBOV/Kik Vero E6 >320 12.0 ± 1.0
EBOV/Gue Vero E6 >320 ≈8
EBOV/Kik HepG2 >80 1.6 ± 0.1
EBOV/Kik HepG2 >320 5.5 ± 0.1
EBOV/Kik Macrophages >320 ≈25
EBOV/Kik Macrophages >320 18.3 ± 0.8
HIV-1 Macrophages 0.002‡ ND
HIV-1 Monocytes 0.69‡ ND
HIV-1 (multiple subtypes) PBMC 0.002–2.5‡ ND
HBV HepG2 (2.2.15) 0.002§ ND

*EBOV, Ebola virus; EC50, 50% effective concentration; BMC, peripheral blood mononuclear cells; ND, not done; HBV, hepatitis B virus.
†EC50s were determined by using an EBOV ELISA with antibodies against glycoprotein or viral matrix protein as described (3).
‡Data from Schinazi (4).
§Data from Kruining et al. (5).

Main Article

References
  1. Cohen  E. Doctor treats Ebola with HIV drug in Liberia–seemingly successfully [videotape]. Atlanta: CNN Health; September 29, 2014. Running time: 2:08 minutes [cited 2014 Oct 28]. http://www.cnn.com/2014/09/27/health/ebola-hiv-drug/index.html?iref=allsearch.
  2. Hart  GJ, Orr  DC, Penn  CR, Figueiredo  HT, Gray  NM, Boehme  RE, Effects of (-)-2'-deoxy-3′-thiacytidine (3TC) 5′-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma. Antimicrob Agents Chemother. 1992;36:1688–94 . DOIPubMedGoogle Scholar
  3. Johansen  LM, Brannan  JM, Delos  SE, Shoemaker  CJ, Stossel  A, Lear  C, FDA-approved selective estrogen receptor modulators inhibit Ebola virus replication Sci Transl Med. 2013;5:190ra79..DOIGoogle Scholar
  4. Schinazi  RF. Assessment of the relative potency of emtricitabine and lamivudine. J Acquir Immune Defic Syndr. 2003;34:243–5, author reply 5–6. DOIPubMedGoogle Scholar
  5. Kruining  J, Heijtink  RA, Schalm  SW. Antiviral agents in hepatitis B virus transfected cell lines: inhibitory and cytotoxic effect related to time of treatment. J Hepatol. 1995;22:263–7. DOIPubMedGoogle Scholar
  6. Furman  PA, Fyfe  JA, St Clair  MH, Weinhold  K, Rideout  JL, Freeman  GA, Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A. 1986;83:8333–7. DOIPubMedGoogle Scholar

Main Article

Page created: February 18, 2015
Page updated: February 18, 2015
Page reviewed: February 18, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external